Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast Cancers.

/PRNewswire/ -- Green3Bio, a subsidiary of Greenfire Bio, today announced a publication in the Journal of Clinical Investigation1 led by researchers at The...

Related Keywords

United States ,Texas ,American ,Greenfire Bio ,Zhen Lu ,Robert Bast ,Steve Morris ,Bajit Gill ,World Cancer Research Fund International ,Linkedin ,University Of Texas Md Anderson Cancer Center ,Facebook ,American Cancer Society ,Cancer Center ,Scientific Advisory Board ,Clinical Investigation ,American Cancer ,World Cancer Research Fund ,Clinical Study ,Recurrent Ovarian ,Primary Peritoneal ,Fallopian Tube Cancers ,Green3bio ,